Conv. Plasma
Nigella Sativa
Peg.. Lambda

All colchicine studies
Meta analysis
Home COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 60 -75% Improvement Relative Risk Mortality, day 30 -100% Ventilation -200% Severe case, day 60 -46% primary Severe case, day 30 -73% primary Colchicine  COLSTAT  LATE TREATMENT  RCT Is late treatment with colchicine + rosuvastatin beneficial for COVID-19? RCT 250 patients in the USA (October 2020 - September 2021) Higher mortality (p=0.54) and ventilation (p=0.28), not sig. Shah et al., BMJ Open, February 2023 Favors colchicine Favors control

Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial

Shah et al., BMJ Open, doi:10.1136/bmjopen-2022-067910, COLSTAT, NCT04472611
Feb 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 250 late stage (80% on oxygen) hospitalized patients in the USA, showing no significant differences with combined colchicine/rosuvastatin treatment.
There was a trend towards increased risk, which authors note may be due to chance because the patients enrolled in the treatment arm were in more serious condition, for example, patients in the treatment arm were more frequently on oxygen, more frequently on HFNC/NIV, and had higher mean SOFA scores.
Colchicine 0.6mg two times daily for 3 days followed by 0.6mg daily, and high-intensity rosuvastatin 40mg daily. This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline.
risk of death, 75.0% higher, RR 1.75, p = 0.54, treatment 7 of 125 (5.6%), control 4 of 125 (3.2%), day 60.
risk of death, 100% higher, RR 2.00, p = 0.50, treatment 6 of 125 (4.8%), control 3 of 125 (2.4%), day 30.
risk of mechanical ventilation, 200.0% higher, RR 3.00, p = 0.28, treatment 6 of 125 (4.8%), control 2 of 125 (1.6%).
risk of severe case, 46.2% higher, RR 1.46, p = 0.34, treatment 19 of 125 (15.2%), control 13 of 125 (10.4%), day 60, primary outcome.
risk of severe case, 72.7% higher, RR 1.73, p = 0.17, treatment 19 of 125 (15.2%), control 11 of 125 (8.8%), day 30, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shah et al., 24 Feb 2023, Randomized Controlled Trial, USA, peer-reviewed, median age 61.0, 23 authors, study period October 2020 - September 2021, this trial uses multiple treatments in the treatment arm (combined with rosuvastatin) - results of individual treatments may vary, trial NCT04472611 (history) (COLSTAT).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Tayyab Shah, Marianne Mccarthy, Irem Nasir, Herb Archer, Elio Ragheb, Jonathan Kluger, Nitu Kashyap, Carlos Paredes, Prashant Patel, Jing Lu, Prakash Kandel, Christopher Song, Mustafa Khan, Haocheng Huang, Faheem Ul Haq, Rami Ahmad, Christopher Howes, Brian Cambi, Gilead Lancaster, Michael Cleman, Charles Dela Cruz, Helen Parise, Dr Alexandra Lansky
BMJ Open, doi:10.1136/bmjopen-2022-067910
Objective To evaluate the effect of colchicine and highintensity rosuvastatin in addition to standard of care on the progression of COVID-19 disease in hospitalised patients. Design A pragmatic, open-label, multicentre, randomised controlled trial conducted from October 2020 to September 2021. Follow-up was conducted at 30 and 60 days. The electronic medical record was used at all stages of the trial including screening, enrolment, randomisation, event ascertainment and follow-up. Setting Four centres in the Yale New Haven Health System. Participants Non-critically ill hospitalised patients with COVID-19. Interventions Patients were randomised 1:1 to either colchicine plus high-intensity rosuvastatin in addition to standard of care versus standard of care alone. Assigned treatment was continued for the duration of index hospitalisation or 30 days, whichever was shorter. Primary and secondary outcome measures The prespecified primary endpoint was progression to severe COVID-19 disease (new high-flow or non-invasive ventilation, mechanical ventilation, need for vasopressors, renal replacement therapy or extracorporeal membrane oxygenation, or death) or arterial/venous thromboembolic events (ischaemic stroke, myocardial infarction, deep venous thrombosis or pulmonary embolism) evaluated at 30 days. Results Among the 250 patients randomised in this trial (125 to each arm), the median age was 61 years, 44% were women, 15% were Black and 26% were Hispanic/ Latino. As part of the standard of care, patients received remdesivir (87%), dexamethasone (92%), tocilizumab (18%), baricitinib (2%), prophylactic/therapeutic anticoagulation (98%) and aspirin (91%). The trial was terminated early by the data and safety monitoring board for futility. No patients were lost to follow-up due to electronic medical record follow-up. There was no significant difference in the primary endpoint at 30 days between the active arm and standard of care arm (15.2% vs 8.8%, respectively, p=0.17). Conclusions In this small, open-label, randomised trial of non-critically ill hospitalised patients with COVID-19, the combination of colchicine and rosuvastatin in addition to standard of care did not appear to reduce the risk of progression of COVID-19 disease or thromboembolic events, although the trial was underpowered due to a lower-than-expected event rate. The trial leveraged the power of electronic medical records for efficiency and improved follow-up and demonstrates the utility of incorporating electronic medical records into future trials. Trial registration NCT04472611.
Ethics approval This study involved human participants and was approved by Yale Institutional Review Board (IRB Protocol ID: 2000027950). Participants gave informed consent to participate in the study before taking part. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement The data contains protected patient information and at this time are not available to be shared publicly. *This analysis excluded all patients in active arm who did not receive both colchicine and rosuvastatin for at least 1 dose in hospital and all patients in standard of care arm who received a single dose of colchicine or any statin in hospital. BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s)
Ackermann, Verleden, Kuehnel, Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19, N Engl J Med, doi:10.1056/NEJMoa2015432
Ayeh, Abbey, Khalifa, Statins use and COVID-19 outcomes in hospitalized patients, PLoS One, doi:10.1371/journal.pone.0256899
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19-final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bikdeli, Madhavan, Jimenez, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review, J Am Coll Cardiol, doi:10.1016/j.jacc.2020.04.031
Caricchio, Abbate, Gordeev, Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.9508
Cariou, Goronflot, Rimbert, Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: results from the CORONADO study, Diabetes Metab, doi:10.1016/j.diabet.2020.10.001
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Fedson, Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and ebola, Ann Transl Med, doi:10.21037/atm.2016.11.03
Gaitán-Duarte, Álvarez-Moreno, Cj, Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial, EClinicalMedicine, doi:10.1016/j.eclinm.2021.101242
Grailer, Canning, Kalbitz, Critical role for the NLRP3 inflammasome during acute lung injury, J Immunol, doi:10.4049/jimmunol.1400368
Group, Colchicine in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial, Lancet Respir Med, doi:10.1016/S2213-2600(21)00435-5
Group, Tocilizumab in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial, Lancet, doi:10.1016/S0140-6736(21)00676-0
Gupta, Madhavan, Poterucha, Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19, Nat Commun, doi:10.1038/s41467-021-21553-1
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2021436
Huang, Cen, Wang, Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia, Lipids Health Dis, doi:10.1186/1476-511X-13-67
Investigators, Atorvastatin versus placebo in patients with COVID-19 in intensive care: randomized controlled trial, BMJ, doi:10.1136/bmj-2021-068407
Kow, Hasan, Meta-analysis of effect of statins in patients with COVID-19, Am J Cardiol, doi:10.1016/j.amjcard.2020.08.004
Kruger, Bailey, Bellomo, A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis, Am J Respir Crit Care Med, doi:10.1164/rccm.201209-1718OC
Lansky, Messé, Brickman, Proposed standardized neurological endpoints for cardiovascular clinical trials: an academic research consortium initiative, J Am Coll Cardiol, doi:10.1016/j.jacc.2016.11.045
Lawler, Goligher, Berger, Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2105911
Leung, Hui, Kraus, Colchicine --update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2015.06.013
Li, Wang, Zhou, Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats, J Geriatr Cardiol, doi:10.3969/j.issn.1671-5411.2013.02.009
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, doubleblinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Marconi, Ramanan, De Bono, Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial, Lancet Respir Med, doi:10.1016/S2213-2600(21)00331-3
Nidorf, Fiolet, Mosterd, Colchicine in patients with chronic coronary disease, N Engl J Med, doi:10.1056/NEJMoa2021372
Oldenburg, Pinsky, Brogdon, Effect of oral azithromycin vs placebo on COVID-19 symptoms in outpatients with SARS-cov-2 infection: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.11517
Patel, Snaith, Thickett, Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (asepsis trial), Crit Care, doi:10.1186/cc11895
Perico, Ostermann, Bontempeill, Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation, J Am Soc Nephrol, doi:10.1681/ASN.V74594
Pope, Tschopp, The role of interleukin-1 and the inflammasome in gout: implications for therapy, Arthritis Rheum, doi:10.1002/art.22938
Pourdowlat, Saghafi, Mozafari, Efficacy and safety of colchicine treatment in patients with COVID-19: a prospective, multicenter, randomized clinical trial, Phytother Res, doi:10.1002/ptr.7319
Reis, Silva, Silva, Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the together randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2021.6468
Shah, Mccarthy, Nasir, Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial, Contemp Clin Trials, doi:10.1016/j.cct.2021.106547
Talasaz, Sadeghipour, Aghakouchakzadeh, Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC state-of-the-art review, J Am Coll Cardiol, doi:10.1016/j.jacc.2021.08.021
Tang, Li, Wang, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, doi:10.1111/jth.14768
Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med, doi:10.1016/S2213-2600(21)00222-8
Tardif, Kouz, Waters, Efficacy and safety of low-dose colchicine after myocardial infarction, N Engl J Med, doi:10.1056/NEJMoa1912388
Thygesen, Alpert, Jaffe, Fourth universal definition of myocardial infarction (2018), J Am Coll Cardiol, doi:10.1016/j.jacc.2018.08.1038
Tikoo, Patel, Kumar, Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications, Biochem Pharmacol, doi:10.1016/j.bcp.2014.11.013
Toldo, Abbate, The NLRP3 inflammasome in acute myocardial infarction, Nat Rev Cardiol, doi:10.1038/nrcardio.2017.161
Vaduganathan, Vardeny, Michel, Renin-angiotensinaldosterone system inhibitors in patients with COVID-19, N Engl J Med, doi:10.1056/NEJMsr2005760
Varga, Flammer, Steiger, Endothelial cell infection and endotheliitis in COVID-19, Lancet, doi:10.1016/S0140-6736(20)30937-5
Viveiros, Rasmuson, Vu, Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones, Am J Physiol Heart Circ Physiol, doi:10.1152/ajpheart.00755.2020
Vora, Lieberman, Wu, Inflammasome activation at the crux of severe COVID-19, Nat Rev Immunol, doi:10.1038/s41577-021-00588-x
Wang, Chen, Yang, Inflammation-associated factors for predicting in-hospital mortality in patients with COVID-19, J Med Virol, doi:10.1002/jmv.26771
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop